Abstract：
UNASSIGNED: Chemotherapeutic agents can have both serious side effects and ototoxicity, which can be caused by direct toxic effects or by metabolic derangement by the agents. Cabazitaxel (CBZ) is a next-generation semi-synthetic taxane derivative that is effective in both preclinical models of human tumors that are sensitive or resistant to chemotherapy and in patients suffering from progressive prostate cancer despite docetaxel treatment. The primary aim of this study is to investigate the ototoxicity of CBZ in a rat model.
UNASSIGNED: : A total of 24 adult male Wistar-Albino rats were equally and randomly divided into four groups. CBZ (Jevtana, Sanofi-Aventis USA) was intraperitoneally administered to Groups 2, 3, and 4 at doses of 0.5, 1.0, and 1.5 mg/kg/week, respectively, for 4 consecutive weeks; Group 1 received only i.p. saline at the same time. At the end of the study, the animals were sacrificed and their cochlea removed for histopathological examination.
UNASSIGNED: : Intraperitoneal administration of CBZ exerted an ototoxic effect on rats, and the histopathological results became worse in a dose-dependent manner (P < 0.05).
UNASSIGNED: : Our findings suggest that CBZ may be an ototoxic agent and can damage the cochlea. More clinical studies should be conducted to understand its ototoxicity.
UNASSIGNED: : A total of 24 adult male Wistar-Albino rats were equally and randomly divided into four groups. CBZ (Jevtana, Sanofi-Aventis USA) was intraperitoneally administered to Groups 2, 3, and 4 at doses of 0.5, 1.0, and 1.5 mg/kg/week, respectively, for 4 consecutive weeks; Group 1 received only i.p. saline at the same time. At the end of the study, the animals were sacrificed and their cochlea removed for histopathological examination.
UNASSIGNED: : Intraperitoneal administration of CBZ exerted an ototoxic effect on rats, and the histopathological results became worse in a dose-dependent manner (P < 0.05).
UNASSIGNED: : Our findings suggest that CBZ may be an ototoxic agent and can damage the cochlea. More clinical studies should be conducted to understand its ototoxicity.
摘要：
■化学治疗剂可具有严重的副作用和耳毒性，这可能是由药物的直接毒性作用或代谢紊乱引起的。卡巴他赛(CBZ)是下一代半合成紫杉烷衍生物,其在对化学疗法敏感或耐受的人类肿瘤的临床前模型和尽管多西他赛治疗但患有进行性前列腺癌的患者中都有效。本研究的主要目的是研究CBZ在大鼠模型中的耳毒性。
■：将24只成年雄性Wistar-Albino大鼠随机平均分为4组。CBZ(Jevtana,Sanofi-AventisUSA）以0.5、1.0和1.5mg/kg/周的剂量腹膜内给予第2、3和4组，分别,连续4周;第1组仅同时接受腹膜内生理盐水。在研究结束时,处死动物,取出它们的耳蜗进行组织病理学检查。
■：腹腔注射CBZ对大鼠有耳毒性作用，组织病理学结果呈剂量依赖性恶化(P<0.05)。
■：我们的研究结果表明，CBZ可能是一种耳毒剂，会损害耳蜗。应进行更多的临床研究以了解其耳毒性。
■：将24只成年雄性Wistar-Albino大鼠随机平均分为4组。CBZ(Jevtana,Sanofi-AventisUSA）以0.5、1.0和1.5mg/kg/周的剂量腹膜内给予第2、3和4组，分别,连续4周;第1组仅同时接受腹膜内生理盐水。在研究结束时,处死动物,取出它们的耳蜗进行组织病理学检查。
■：腹腔注射CBZ对大鼠有耳毒性作用，组织病理学结果呈剂量依赖性恶化(P<0.05)。
■：我们的研究结果表明，CBZ可能是一种耳毒剂，会损害耳蜗。应进行更多的临床研究以了解其耳毒性。
